Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP982593priorityCriticalpatent/ECSP982593A/en
Publication of ECSP982593ApublicationCriticalpatent/ECSP982593A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Un método para el tratamiento de la diabetes mellitus y las condiciones asociadas con la diabetes mellitus en un mamífero, método que comprende administrar una cantidad efectiva, no tóxica y farmacéuticamente aceptable de un sensibilizador de insulina y una cantidad sub-máxima de un secretagogo de insulina, a un mamífero que lo necesita; y una composición farmacéutica para empleo de dichos métodos.A method for the treatment of diabetes mellitus and the conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective, non-toxic and pharmaceutically acceptable amount of an insulin sensitizer and a sub-maximum amount of an insulin secretagogue. , to a mammal that needs it; and a pharmaceutical composition for use of said methods.
ECSP9825931998-07-161998-07-16
NEW METHOD OF TREATMENT VI
ECSP982593A
(en)
USE OF AN INSULIN SENSITIZER AND AN ANTI-HYPERGLYCEMIC AGENT FOR THE PREPARATION OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH SENSITIZER AND SUCH AGENT.
Pharmaceutical composition comprising: i) an at1 receptor antagonist or a salt, ii) an insulin sensitizer or a salt and iii) a pharmaceutically acceptable carrier; use for the prevention, delay of progress or treatment of hypertension, diabetes, among others (div. sol. 2034-01).
USE OF AN INSULIN SENSITIZER AND AN ANTI-HYPERGLYCEMIC AGENT FOR THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF DIABETES MELLITUS AND CONDITIONS ASSOCIATED WITH IT AND A PHARMACEUTICAL COMPOSITION.